期刊文献+

聚乙二醇干扰素治疗不同基因型慢性丙型肝炎的药物经济学评价 被引量:1

Pharmacoeconomics evaluation of pegylated interferon for treating different genotypes of chronic hepatitis C
收藏 分享 导出
摘要 目的:评价与普通干扰素相比,聚乙二醇干扰素α-2a对于不同基因型的中国慢性丙型肝炎患者的经济性。方法:将慢性丙型肝炎患者分为基因1型和非基因1型,分别构建疾病进展Markov模型,比较聚乙二醇干扰素α-2a和普通干扰素的长期成本-效用,并对结果进行敏感性分析。结果:与普通干扰素相比,聚乙二醇干扰素α-2a对于基因1型患者成本更低(183 631.14元vs 212 703.42元)、效用更高(14.06QALY vs 12.32 QALY),聚乙二醇干扰素α-2a更具有经济性;对于非基因1型患者,聚乙二醇干扰素α-2a成本更高(112 770.18元vs 111 025.80元)、效用更高(15.01 QALY vs 14.51 QALY),增量成本-效用比3 488.76元/QALY(低于中国阈值),聚乙二醇干扰素α-2a更具有经济性。敏感性分析与基础分析一致。结论:对于不同基因型中国慢性丙型肝炎患者,聚乙二醇干扰素α-2a均为更经济的治疗方案。 Objective: To evaluate the pharmacoeconomics of pegylated interferon α-2a and interferon based on Chinese patients with different genotypes of chronic hepatitis C. Methods: The chronic hepatitis C patients were divided into genotype 1 and non-genotype 1. Markov models were built,respectively,to simulate developmental process of chronic hepatitis C in Chinese patients. We evaluated the cost and utility of pegylated interferon α-2a and interferon by running 50 cycles of the models,and carried out sensitivity analysis. Results:Cost-utility analysis results showed that for patients with genotype 1 chronic hepatitis C,pegylated interferon α-2a had lower cost( 183 631. 14 RMB vs 212 703. 42 RMB) and higher utility( 14. 06 QALY vs 12. 32 QALY),which proved that pegylated interferon α-2a was cost-effective. With regard to non-genotype 1 patients,pegylated interferonα-2a had higher cost( 112 770. 18 RMB vs 111 025. 80 RMB) and higher utility( 15. 01 QALY vs 14. 51 QALY),and the incremental cost-utility ratio was 3 488. 76 RMB/QALY( lower than Chinese threshold),so pegylated interferon α-2a was cost-effective. In the sensitivity analysis,the results were similar with base case analysis.Conclusion: Pegylated interferon α-2a is more cost-effctive than interferon for patients with both genotype 1 and non-genotype 1 chronic hepatitis C in China.
作者 陈平钰 刘国恩 徐菲 马爱霞 CHEN Ping-yu1,LIU Guo-en2,XU Fei3,MA Ai-xia1(1School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China ; 2 China Center for Health Economic Research, Peking University, Beijing 100871, China; 3 School of Public Health, Fadan University, Shanghai 200433, China)
出处 《中国新药杂志》 CSCD 北大核心 2017年第15期1736-1743,共8页 Chinese Journal of New Drugs
关键词 慢性丙型肝炎 干扰素 MARKOV模型 成本-效用分析 药物经济学评价 chronic hepatitis C interferon Markov model cost-utility analysis pharmacoeconomics evaluation
作者简介 [作者简介]陈平钰,女,博士,主要从事药物经济学研究。联系电话:15195876106,E—mail:chenpingyu220@163.com。 [通讯作者]马爱霞,女,教授,博士生导师,主要从事药物经济学研究。联系电话:13809028488,E-mail:ma86128@sina.com。
  • 相关文献

参考文献24

二级参考文献301

共引文献295

同被引文献9

引证文献1

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈